Raiany Romanni-Klein is a Harvard and Brown-trained bioethicist focused on understanding why secular people like to narrate death and aging as good things, and quantifying the economic impacts of such narratives. She worked with legends like George Church and Steven Pinker on her PhD, and also played a central role in designing the $101 million dollar XPRIZE for Healthspan, the largest science prize ever awarded.

Raiany is also the founder of a new think tank designed to study and streamline progress in America’s science and technology, and most recently published a paper demonstrating that delaying overall biological aging by just one year could yield $27 trillion dollars in net present value.

Today’s conversation is focused on the ethics and economics of longevity.

Martin Borch Jensen is a scientist, entrepreneur and longevity advocate. He is the co-founder and CSO of Gordian Biotechnology, a company whose platform enables the simultaneous delivery and testing of hundreds of therapeutics in individual animals. They have raised over $60M from top investors like Founders Fund, Horizons Ventures, Fifty Years and the Longevity Fund. They also recently announced a partnership with Pfizer to apply Gordian’s proprietary mosaic screening platform to accelerate the discovery of therapeutic targets for obesity.

Martin is also a prominent voice in the longevity community and activist. As founder and president of Norn Group, a do tank for longevity, he launched the Impetus Grants program, which has deployed roughly $34 million to scientists across 145 projects, with funding decisions made within 3 weeks to enable speed.

In our conversation today, we cover the state of the longevity field, its major bottlenecks, theories of aging, the role of AI in longevity, and much more.

Today’s guest is Karl Pfleger. After spending a decade as one of the first AI researchers at Google from 2002 to 2011, he has dedicated himself to the cause of rejuvenation biotechnology for nearly a decade. He is a philanthropist, community builder, and prolific angel investor with over 35 investments into rejuvenation biotech startups. His website, agingbiotech.info, provides valuable information to the entire field, and his talks and X posts are highly insightful and influential within longevity.

Karl has deeply researched and nuanced takes, and those really show in this conversation. We’ll cover why epigenetic reprogramming won’t solve aging, Karl’s investment strategy and what distinguishes true rejuvenation technology, and why better diagnostic technologies could be the key to personalized aging interventions.

Dr. Daniel Ives is the founder of Shift Bioscience. Shift has built a novel single-cell aging clock that has enabled them to run high-throughput screens to discover genes that regulate aging, with the goal of identifying a therapy to systemically reverse aging.

We’ll dive deep into Shift’s latest work on SB000, a germline-expressed gene that rejuvenates cells without inducing pluripotency, and SB101, a pro-aging gene whose inhibition both reverses cellular age and prevents fibrosis, opening a clear path to clinical development.

Daniel also shares his philosophy on why reversing aging might be easier than we think, the coming cultural shift when anti-aging drugs become mundane reality, and why he won't rest until we can double human lifespan.

Polyphron is led by co-founder and CEO Matthew Osman, a twice-exited tech entrepreneur turned biotech founder. Matthew is building a computation-first tissue foundry that applies AI and lab automation to semi-autonomously replicate human tissues in a dish. Polyphron aims to create the world’s most efficient tissue foundry for regenerative medicine.

Listen to this episode to learn more about the core bet and technological platform at Polyphron, the remarkable progress they’ve made on two programs in heart and brain tissue in just a year, and what’s next for the company.

Dr. Omri Amirav-Drory is a General Partner at NFX whose mission in life is to end involuntary death. Omri has backed companies like Mammoth Biosciences, Immunai, and Centivax, and has earned a reputation as one of the most respected seed investors in tech-enabled life sciences and longevity. He previously founded Genome Compiler and sold it to Twist Bioscience, which is now worth $2.5 billion. We’ll talk about why longevity research could solve America's biggest economic problems, Omri’s 4 step ABCD plan for beating death, and why AI alone won’t solve aging.

Dr. Jacob Kimmel is the President of NewLimit, a biotechnology company developing reprogramming medicines to treat age-related disease and extend human healthspan. Dr. Kimmel co-founded the company with Blake Byers and Bryan Armstrong, and has since raised over $300M from top venture capital funds like Kleiner Perkins, Dimension, Founders Fund, and Khosla Ventures. They expect to initiate their first clinical trial in a few years.

Dr. Kimmel has garnered a reputation as one of the brightest minds in longevity and the intersection between artificial intelligence and molecular biology, and NewLimit is often cited as one of the most important companies building in longevity today.

Adam Gries is a serial entrepreneur with four successful exits, and products that have reached over eighty million users. He has now set his sights on creating a longevity revolution through his organization Vitalism. Vitalism is a moral philosophy and community of action, forming a revolutionary movement to get humanity to fight as hard as possible to achieve unlimited lifespans in peak health.

Our conversation covers the state of the longevity field today, the myth of billionaires’ obsession with longevity, what it will take to revolutionize our culture and industry to treat aging seriously, and much more.